ANL 33.80 Increased By ▲ 1.05 (3.21%)
ASC 15.13 Increased By ▲ 0.75 (5.22%)
ASL 25.50 No Change ▼ 0.00 (0%)
AVN 95.50 Decreased By ▼ -0.20 (-0.21%)
BOP 9.17 Increased By ▲ 0.02 (0.22%)
BYCO 10.23 Increased By ▲ 0.25 (2.51%)
DGKC 137.50 Increased By ▲ 2.20 (1.63%)
EPCL 51.62 Increased By ▲ 0.37 (0.72%)
FCCL 25.00 Increased By ▲ 0.31 (1.26%)
FFBL 25.45 Increased By ▲ 0.95 (3.88%)
FFL 15.70 Increased By ▲ 0.28 (1.82%)
HASCOL 10.90 Increased By ▲ 0.18 (1.68%)
HUBC 86.75 Increased By ▲ 0.01 (0.01%)
HUMNL 7.10 No Change ▼ 0.00 (0%)
JSCL 27.04 Increased By ▲ 0.45 (1.69%)
KAPCO 40.00 Increased By ▲ 0.80 (2.04%)
KEL 4.15 Increased By ▲ 0.04 (0.97%)
LOTCHEM 14.80 Increased By ▲ 0.08 (0.54%)
MLCF 47.59 Increased By ▲ 0.75 (1.6%)
PAEL 38.30 Increased By ▲ 1.20 (3.23%)
PIBTL 11.91 Increased By ▲ 0.08 (0.68%)
POWER 10.70 Increased By ▲ 0.20 (1.9%)
PPL 90.97 Decreased By ▼ -0.53 (-0.58%)
PRL 27.45 Increased By ▲ 1.63 (6.31%)
PTC 8.81 Decreased By ▼ -0.09 (-1.01%)
SILK 1.40 No Change ▼ 0.00 (0%)
SNGP 43.75 Increased By ▲ 2.68 (6.53%)
TRG 147.70 No Change ▼ 0.00 (0%)
UNITY 31.20 Increased By ▲ 0.72 (2.36%)
WTL 1.52 Decreased By ▼ -0.02 (-1.3%)
BR100 5,016 Increased By ▲ 30.84 (0.62%)
BR30 26,130 Increased By ▲ 297.73 (1.15%)
KSE100 46,158 Increased By ▲ 193.53 (0.42%)
KSE30 19,308 Increased By ▲ 71.8 (0.37%)
Pakistan

Pakistan likely to receive Pfizer-BioNTech vaccine under COVAX programme

  • The WHO signed an advance purchase agreement with the American pharmaceutical, where it will receive at least 40 million doses of the drug.
  • It also anticipates another 50 million doses from UK-based pharmaceutical Oxford-Astrazeneca. As per the existing agreement with the company, the shipment will be made in first quarter of the year.
26 Jan 2021

Under World Health Organization's COVAX programme, Pakistan is likely to receive Pfizer-BioNTech vaccine in the first quarter of the year.

The WHO signed an advance purchase agreement with the American pharmaceutical, where it will receive at least 40 million doses of the drug, which has been approved for emergency use by the global health body.

As per the statement issued last week, the vaccine rollout will commence with the "successful negotiation and execution of supply agreements."

COVAX also confirmed it would receive first 100 million doses of the Oxford-Astrazeneca vaccine manufactured by the Serum Institute of India (SII) under an existing agreement with the Indian firm.

It also anticipates another 50 million doses from UK-based pharmaceutical Oxford-Astrazeneca. As per the existing agreement with the company, the shipment will be made in first quarter of the year.

The COVAX initiative ensures “rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level”.

Of the 190 participating economies, Pakistan is among the 92 that qualify for the financial mechanism Gavi COVAX AMS.

The facility guarantees access to 2 billion doses of approved vaccines and aims to protect at least 20% of each participating population by the end of the year – unless a participant has requested a lower percentage of doses.

"At least 1.3 billion of these doses will be made available to the 92 economies eligible for the Gavi COVAX AMC by the end of 2021.